Advantage Alpha Capital Partners LP Increases Stake in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Advantage Alpha Capital Partners LP significantly increased its stake in ANI Pharmaceuticals by 37,674.1% during the first quarter, owning a total of 10,199 shares valued at around $683,000.
• Insider transactions revealed that Director Jeanne Thoma and COO Muthusamy Shanmugam sold substantial shares amounting to $26.26 million over the last three months, indicating a decrease in their ownership percentages.
• ANI Pharmaceuticals reported a strong EPS of $1.80 for the latest quarter, surpassing estimates, and achieved revenue growth of 53.2% year-over-year.

Advantage Alpha Capital Partners LP raised its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 37,674.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,199 shares of the specialty pharmaceutical company's stock after buying an additional 10,172 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in ANI Pharmaceuticals were worth $683,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. Hohimer Wealth Management LLC grew its holdings in shares of ANI Pharmaceuticals by 5.2% in the first quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock valued at $334,000 after purchasing an additional 247 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of ANI Pharmaceuticals by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock valued at $582,000 after purchasing an additional 364 shares in the last quarter. MetLife Investment Management LLC grew its holdings in shares of ANI Pharmaceuticals by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 11,397 shares of the specialty pharmaceutical company's stock valued at $630,000 after purchasing an additional 675 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after purchasing an additional 881 shares in the last quarter. Finally, National Bank of Canada FI purchased a new position in shares of ANI Pharmaceuticals in the first quarter valued at $79,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, Director Jeanne Thoma sold 21,540 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $89.15, for a total value of $1,920,291.00. Following the completion of the transaction, the director directly owned 23,405 shares in the company, valued at approximately $2,086,555.75. The trade was a 47.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Muthusamy Shanmugam sold 52,990 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $87.15, for a total value of $4,618,078.50. Following the sale, the chief operating officer owned 531,920 shares in the company, valued at $46,356,828. The trade was a 9.06% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 301,247 shares of company stock valued at $26,264,427 in the last three months. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $93.00 target price (up from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Guggenheim reaffirmed a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research note on Monday, August 11th. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Finally, Piper Sandler reiterated an "overweight" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $84.75.

ANI Pharmaceuticals Stock Performance

ANIP stock opened at $91.14 on Friday. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The business has a 50-day moving average price of $70.06 and a 200 day moving average price of $65.69. The company has a market capitalization of $1.98 billion, a P/E ratio of -118.36 and a beta of 0.61. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $91.54.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The business had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm's revenue was up 53.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.02 earnings per share. As a group, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.